Sana Biotechnology (SANA) Goldman Sachs Cell Therapy Day summary

Industry outlook and scientific advancements

• Allogeneic cell therapy is positioned as the next frontier, aiming to democratize access and scalability beyond autologous approaches, especially for hematologic malignancies and autoimmune diseases.

• Overcoming immune rejection is central, with strategies like 'cloak' (immune evasion) and 'dagger' (counteracting alloreactive T-cells) being developed and implemented.

• Manufacturing science and facility investments are enabling large-scale, cost-effective production, with single sites capable of producing doses for tens of thousands of patients annually.

• The field is advancing toward reducing or eliminating lymphodepletion, a key barrier for broader adoption, especially in autoimmune indications.

• Gene engineering and modularity in allogeneic products allow for rapid innovation and adaptation to resistance mechanisms.

Clinical pipeline updates and trial progress

• Lead allogeneic CAR T program cema-cel is being advanced into frontline large B-cell lymphoma as a consolidation therapy for MRD-positive patients, with pivotal trial milestones expected through 2027.

• ALLO-316, a CD70-directed CAR T for renal cell carcinoma, showed ~30% response rate in early data, with further updates and dose optimization expected by year-end.

• ALLO-329, a dual CD19/CD70 CAR for autoimmune diseases, leverages CRISPR-based editing and aims to address both B- and T-cell components of autoimmunity, with IND submission planned for Q1 2025 and proof-of-concept data by year-end 2025.

• Early phase I data for SC291 (CD19) in autoimmune and B-cell malignancies show promising safety and B-cell depletion, with further durability and efficacy data pending.

• Investigator-sponsored trials in type 1 diabetes are testing gene-modified islet cell therapies, aiming to eliminate the need for immunosuppression and demonstrate functional cell survival.

Commercialization, scalability, and competitive landscape

• Allogeneic therapies offer significant logistical and scalability advantages, removing the need for complex autologous manufacturing and enabling off-the-shelf availability.

• Manufacturing advances and gene editing are reducing costs and cell dose requirements, supporting broader patient access.

• Site activation and patient recruitment remain time-consuming but are not seen as major rate-limiting factors as the field matures and awareness grows among clinicians.

• The competitive landscape is evolving, with differentiation strategies focusing on unique clinical trial designs, target selection, and manufacturing innovations.

• Solid tumor applications and further gene engineering are highlighted as major future growth areas for allogeneic cell therapies.